Adarx is like the next-generation Alnylam Pharmaceuticals (ALNY), developing advanced siRNA therapies for a wider range of diseases including those beyond the liver.

• Therapeutics for Complement-Mediated Diseases: siRNA therapeutic candidates designed to treat various diseases caused by an overactive complement system.
• Therapeutics for Hereditary Angioedema (HAE): siRNA therapeutic candidates specifically aimed at treating hereditary angioedema.
• Therapeutics for Thrombotic Diseases: siRNA therapeutic candidates in development for the treatment of diseases involving blood clot formation.
• Therapeutics for Obesity: Preclinical siRNA therapeutic candidates targeting adipose tissue for the treatment of obesity.
• Therapeutics for Neurodegenerative Diseases: Preclinical siRNA therapeutic candidates targeting neurons for the treatment of neurodegenerative conditions, including Alzheimer's.

Adarx Pharmaceuticals (ADRX) is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics. As a company in this stage, it does not currently sell its therapeutic products directly to individuals (patients). Instead, its primary revenue streams come from collaboration and licensing agreements with other pharmaceutical companies.

Based on the provided information, Adarx Pharmaceuticals has a significant agreement with:

• AbbVie (ABBV)

This collaboration involves an upfront cash payment, potential option extension and exercise payments, contingent milestone payments, and tiered royalties, indicating a substantial business-to-business relationship where AbbVie is a major customer/partner for Adarx's technology and development efforts.

Zhen Li, Ph.D. President, Chief Executive Officer and Director

Dr. Li is a co-founder of ADARx Pharmaceuticals and has over two decades of diverse experience in research and development within the pharmaceutical and biotech industries. Prior to ADARx, she served as Senior VP at Arrowhead Pharmaceuticals, where she led the discovery and non-clinical development of their delivery platform and multiple product candidates. Earlier, she was a director at Merck, focusing on siRNA development. ADARx is her first role as CEO.

Ryan Fisk, M.B.A. Chief Financial Officer and Chief Business Officer

Mr. Fisk joined ADARx with more than two decades of experience in investment banking, advising biotech and other innovative growth companies on financial and corporate development strategy. He previously served as Managing Director in the Healthcare Investment Banking Group at Goldman Sachs, with a focus on the biotech industry since 2012. His prior experience also includes senior leadership roles in the Healthcare Investment Banking Groups at Bank of America Merrill Lynch and Credit Suisse. Mr. Fisk has advised on biotech financing transactions totaling over $60 billion and M&A and partnership transactions totaling over $75 billion.

A. Robert MacLeod, Ph.D. Chief Scientific Officer

Dr. MacLeod joined ADARx as Chief Scientific Officer, bringing extensive experience in the oligonucleotide field. He earned his Ph.D. in Cancer Epigenetics from McGill University.

Rui Zhu, Ph.D. Chief Technology Officer

Dr. Zhu is a founding member of ADARx and an experienced drug hunter with a track record in the oligonucleotide field. Before joining ADARx, he was a Program Lead at Arrowhead Pharmaceuticals, where he co-led five siRNA discovery programs to Phase I clinical trials.

Robert Ackles Chief People Officer

Mr. Ackles joined ADARx as Chief People Officer, contributing nearly three decades of biopharmaceutical leadership experience. He has a proven record of building people strategies that support growth, culture, and execution. Previously, Mr. Ackles served for ten years as Senior Vice President, Chief People Officer at Acadia Pharmaceuticals, leading human resources and talent initiatives. He also held leadership roles at Santarus Pharmaceuticals and TAP Pharmaceuticals.

Key Risks for Adarx Pharmaceuticals (ADRX)

1. Clinical Development and Product Failure Risk: As a late-clinical stage biotechnology company, Adarx Pharmaceuticals' success is highly dependent on the successful development, regulatory approval, and commercialization of its therapeutic candidates. The company currently has three clinical-stage and two advanced preclinical programs. Clinical trials are inherently uncertain, and there is a significant risk that these candidates may fail to demonstrate efficacy or safety, experience delays, or encounter other challenges that could lead to their termination, resulting in substantial financial losses and a negative impact on the company's prospects.

2. Proprietary Technology Efficacy for Extrahepatic Delivery: Adarx aims to expand its pipeline beyond established liver-directed applications into extrahepatic tissues (such as adipose and neurons) using its Cell Targeted Delivery (CTD) technology. The background information explicitly states that the broader potential of siRNA therapeutics has historically been constrained by challenges in achieving potent, durable, and selective silencing outside of liver-directed applications. There is a risk that Adarx's proprietary CTD technology may not successfully overcome these historical limitations, which could impede the development and success of its extrahepatic programs and limit the company's long-term growth potential.

3. Dependence on Collaboration Success and Milestone Achievement: Adarx Pharmaceuticals entered into a discovery-stage Collaboration and License Option Agreement with AbbVie. While this agreement provided an upfront cash payment, a significant portion of the potential value comes from contingent option extension and exercise payments, up to $7.45 billion in additional contingent milestone payments, and tiered royalties. As a discovery-stage collaboration, the successful advancement, development, and commercialization of therapeutics under this agreement are highly uncertain. There is a substantial risk that these future milestone payments and royalties may not materialize, or may be significantly less than the maximum potential, thereby impacting Adarx's future revenue streams and financial outlook.

Adarx Pharmaceuticals (ADRX) is focused on developing siRNA therapeutics for a range of diseases. The addressable markets for their main product candidates are as follows:

• Complement-mediated diseases: The global market for complement inhibitors was valued at approximately USD 9.00 billion in 2025 and is projected to reach USD 32.40 billion by 2034, growing at a compound annual growth rate (CAGR) of 15.40%. North America accounted for 56.44% of this market in 2025. Another estimate indicates the global complement inhibitors market size was valued at USD 12.56 billion in 2025 and is projected to reach USD 28.65 billion by 2035, with North America holding 68% of the market share.
• Hereditary Angioedema (HAE): The global hereditary angioedema treatment market size was valued at USD 6.53 billion in 2025 and is projected to grow to USD 27.06 billion by 2034, exhibiting a CAGR of 17.12%. North America held a significant share of 90.66% of this market in 2025.
• Thrombotic diseases: The global thrombus treatment market size was estimated at USD 40.27 billion in 2024 and is projected to grow to USD 81.11 billion by 2035, at a CAGR of 6.57%. North America is the largest market for thrombus treatment, accounting for approximately 45% of the global share. The global thrombosis drugs market size was valued at USD 28.57 billion in 2025 and is projected to reach USD 57.90 billion by 2034, with a CAGR of 8.16%.
• Obesity: The global obesity medicines market reached USD 66 billion in 2025 and is forecast to rise to USD 92 billion in 2026, with projections reaching between USD 105 billion and USD 200 billion by 2027 and beyond. Morgan Stanley Research estimates the global market for obesity drugs could reach USD 150 billion at its peak in 2035. The U.S. obesity therapeutics market size in 2025 was approximately USD 13 billion.
• Neurodegenerative diseases (including Alzheimer’s): The global neurodegenerative disease market size was valued at USD 59.06 billion in 2025 and is projected to grow to USD 109.50 billion by 2034, registering a CAGR of 7.1%. North America dominated this market with a 42.35% share in 2025. Specifically for Alzheimer's therapeutics, the global market size accounted for USD 6.49 billion in 2025 and is predicted to increase to approximately USD 38.61 billion by 2035, expanding at a CAGR of 19.52%. North America held the largest share of 46.10% in the global Alzheimer therapeutics market in 2025.

Adarx Pharmaceuticals (ADRX) is expected to drive future revenue growth over the next 2-3 years through several key avenues:

1. Milestone and Royalty Payments from AbbVie Collaboration: Adarx entered into a significant Collaboration and License Option Agreement with AbbVie in May 2025. This agreement includes eligibility for additional payments of up to $385.0 million in option extension and option exercise payments, up to $7.45 billion in additional contingent milestone payments, and tiered royalties at rates in the high single digits to mid-teens. The achievement of these milestones and potential royalty generation from partnered programs will be a significant revenue driver in the near to medium term.
2. Advancement of Clinical-Stage Pipeline: The company has three wholly-owned clinical-stage therapeutic candidates targeting complement-mediated diseases, hereditary angioedema (HAE), and thrombotic diseases. Successful progression of these candidates through clinical trials towards potential regulatory approval and commercialization would be a primary driver of future revenue, either through direct sales or further partnership opportunities.
3. Expansion into Extrahepatic Therapeutic Areas: Adarx is utilizing its Cell Targeted Delivery (CTD) technology to expand beyond liver-directed applications into extrahepatic tissues. Two programs are in or advancing to the investigational new drug application (IND)-enabling stage, targeting adipose (obesity) and neurons (neurodegenerative diseases including Alzheimer’s). Successful advancement of these programs into clinical development represents expansion into new and large therapeutic markets, potentially leading to new collaborations, milestone payments, or future product sales.
4. Leveraging Proprietary Technologies for New Partnerships: Adarx's messenger RNA (mRNA) Silencing Technology (MST) and Cell Targeted Delivery (CTD) are proprietary platforms designed to optimize siRNA sequences and delivery. The success of these technologies in their internal pipeline and the existing AbbVie collaboration could attract additional strategic partnerships or licensing agreements with other pharmaceutical companies across various therapeutic areas, generating further upfront payments, milestones, and royalties.

Inbound Investments

• In May 2025, Adarx Pharmaceuticals entered into a discovery-stage Collaboration and License Option Agreement with AbbVie.
• Adarx Pharmaceuticals received an upfront cash payment of $335.0 million from AbbVie.
• The company is eligible to receive additional payments of up to $385.0 million in option extension and option exercise payments, and up to $7.45 billion in additional contingent milestone payments, plus tiered royalties.